High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Department of Hematology and Oncology, Charité Berlin, Berlin, Germany.
The Lancet Oncology (Impact Factor: 24.69). 10/2010; 11(11):1036-47. DOI: 10.1016/S1470-2045(10)70229-1
Source: PubMed


High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma. The role of whole brain radiotherapy is controversial because delayed neurotoxicity limits its acceptance as a standard of care. We aimed to investigate whether first-line chemotherapy based on high-dose methotrexate was non-inferior to the same chemotherapy regimen followed by whole brain radiotherapy for overall survival.
Immunocompetent patients with newly diagnosed primary CNS lymphoma were enrolled from 75 centres and treated between May, 2000, and May, 2009. Patients were allocated by computer-generated block randomisation to receive first-line chemotherapy based on high-dose methotrexate with or without subsequent whole brain radiotherapy, with stratification by age (<60 vs ≥60 years) and institution (Berlin vs Tübingen vs all other sites). The biostatistics centre assigned patients to treatment groups and informed local centres by fax; physicians and patients were not masked to treatment group after assignment. Patients enrolled between May, 2000, and August, 2006, received high-dose methotrexate (4 g/m(2)) on day 1 of six 14-day cycles; thereafter, patients received high-dose methotrexate plus ifosfamide (1·5 g/m(2)) on days 3-5 of six 14-day cycles. In those assigned to receive first-line chemotherapy followed by radiotherapy, whole brain radiotherapy was given to a total dose of 45 Gy, in 30 fractions of 1·5 Gy given daily on weekdays. Patients allocated to first-line chemotherapy without whole brain radiotherapy who had not achieved complete response were given high-dose cytarabine. The primary endpoint was overall survival, and analysis was per protocol. Our hypothesis was that the omission of whole brain radiotherapy does not compromise overall survival, with a non-inferiority margin of 0·9. This trial is registered with, number NCT00153530.
551 patients (median age 63 years, IQR 55-69) were enrolled and randomised, of whom 318 were treated per protocol. In the per-protocol population, median overall survival was 32·4 months (95% CI 25·8-39·0) in patients receiving whole brain radiotherapy (n=154), and 37·1 months (27·5-46·7) in those not receiving whole brain radiotherapy (n=164), hazard ratio 1·06 (95% CI 0·80-1·40; p=0·71). Thus our primary hypothesis was not proven. Median progression-free survival was 18·3 months (95% CI 11·6-25·0) in patients receiving whole brain radiotherapy, and 11·9 months (7·3-16·5; p=0·14) in those not receiving whole brain radiotherapy. Treatment-related neurotoxicity in patients with sustained complete response was more common in patients receiving whole brain radiotherapy (22/45, 49% by clinical assessment; 35/49, 71% by neuroradiology) than in those who did not (9/34, 26%; 16/35, 46%).
No significant difference in overall survival was recorded when whole brain radiotherapy was omitted from first-line chemotherapy in patients with newly diagnosed primary CNS lymphoma, but our primary hypothesis was not proven. The progression-free survival benefit afforded by whole brain radiotherapy has to be weighed against the increased risk of neurotoxicity in long-term survivors.

25 Reads
    • "Although a beneficial role for surgery could not have been detected, the authors outlined the need for complete resection in patients with large and space-occupying lesion in whom neurological deterioration had been documented [4]. In accordance, the G-PCNSL-SG-1 trial has demonstrated an improved PFS and OS in patients receiving surgical resection compared to biopsy only [18]. This effect was not due to differences in KPS or age, but was significantly more pronounced in patients with singular lesions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Growth and progress of primary central nervous lymphoma (PCNSL) severely disrupt the blood brain barrier (BBB). Such disruptions can be intraoperatively visualized by injecting fluorescein sodium (FL) and applying a YELLOW 560nm surgical microscope filter. Here, we report a small cohort of patients with PCNSL that mimicked high grade gliomas (HGG) or cerebral metastases (CM), who had been operated on with the use of FL. Patients and methods: Retrospectively, seven patients with PCNSL were identified, who had been operated on by means of microsurgery after intravenous FL injection. The surgical reports were screened for statements on the grade of fluorescent staining in the tumor area. One representative case was chosen to show the staining under white light as well as under filtered light at different distances to the tumor area. Results: All patients had shown bright and homogenous fluorescent staining of the tumor (n=7. 100%). No adverse effects had been observed. Conclusion: Similar to patients with HGG or CM, patients with PCNSL may benefit from use of FL and the dedicated YELLOW 560nm filter in open surgery.
    Clinical neurology and neurosurgery 09/2015; 139. DOI:10.1016/j.clineuro.2015.09.015 · 1.13 Impact Factor
  • Source
    • "Studies on replacement of WBRT with conventional chemotherapy are still limited [8,9]. Findings of a phase 3 randomized clinical trial (G-PCNSL-SG-1) showed no significant difference in overall survival (OS) when WBRT was skipped after first-line chemotherapy, however, a disadvantage in progression-free survival (PFS) was proven regardless of chemotherapy response [10]. Therefore, it was thought that the benefit of WBRT in terms of PFS outweighed the increased risk of NT. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.
    Cancer Research and Treatment 07/2014; 46(3):261-269. DOI:10.4143/crt.2014.46.3.261 · 3.32 Impact Factor
  • Source
    • "Following introduction of HD-MTX-based chemotherapy, WBRT (36-45Gy) has continued to be employed to consolidate responses and provide more durable disease control. Delayed neurotoxicity [58, 59•], however, is a major limitation that is clinically evident in approximately one-third of patients, particularly with increasing age, and associated with significant morbidity and mortality. The only phase III trial thus far to complete accrual in PCNSL aimed to demonstrate that omission of consolidation WBRT after MTX-based chemotherapy resulted in non-inferior OS rates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is an aggressive malignancy that exhibits unique biological features and characteristic clinical behaviour, with overall long-term survival rates of around 20-40 %. Clinical outcome has improved following the advent of chemoradiation protocols incorporating high-dose methotrexate in the mid-1980s, but disease relapse and adverse neurocognitive sequelae remain major clinical challenges. To address this, investigators have focused on improving drug therapy with novel cytotoxic combinations, monoclonal antibody therapy, and intensive chemotherapy consolidation approaches, in an attempt to improve disease control whilst reducing the requirement for whole-brain radiotherapy. Outcomes for patients that are older, immunocompromised, or have relapsed/refractory disease remain unsatisfactory and there is a paucity of clinical trial data to guide treatment of these groups. This review highlights recent advances in pathobiology, imaging, and clinical management of PCNSL and looks ahead to research priorities for this rare and challenging lymphoid malignancy.
    Current Hematologic Malignancy Reports 06/2014; 9(3). DOI:10.1007/s11899-014-0217-2 · 2.20 Impact Factor
Show more